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ImmunomodulationAims: The incidence of secondary systemic fungal infections has sharply increased in bacterial septic patients.
Antimycotics exhibit immunomodulatory properties, yet these effects are incompletely understood in secondary
systemic fungal infections following bacterial sepsis.We investigated amodel of systemic inﬂammation to deter-
mine whether antimycotics (liposomal amphotericin B (L-AMB), itraconazol (ITC), and anidulafungin (ANI))
modulate the gene and protein expression as well as the phagocytic activity of lipopolysaccharide (LPS)-stimu-
lated human monocytes.
Main methods: THP-1 monocytes were incubated with L-AMB, ITC or ANI and LPS. Gene expression levels of cy-
tokines (TNF-balphaN, IL-1bbetaN, IL-6, and IL-10) were measured after 2 h, 6 h, and 24 h. Cytokine protein
levelswere evaluated after 24 h andphagocytic activitywas determined following co-incubationwith Escherichia
coli.
Key ﬁndings: All antimycotics differentiallymodulated the gene and protein expression of cytokines in sepsis-like
conditions. In the presence of LPS, we identiﬁed L-AMB as immunosuppressive, whereas ITC demonstrated pro-
inﬂammatory properties. Both compounds induced remarkably less phagocytosis.
Signiﬁcance: Our study suggests that antimycotics routinely used in septic patients alter the immune response in
sepsis-like conditions bymodulating cytokine gene and protein expression levels and phagocytic activity. Future
treatment strategies should consider the immune status of the host and apply antimycotics accordingly in bacte-
rial septic patients with secondary fungal infections.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of severe sepsis and septic shock remains high with
considerable mortality ranging between 22% and 76% [1–3]. The treat-
ment of fungal infections has become a major problem due to a rising
number of immunocompromised patients, more invasive interventions
and an increasing number of older individuals hospitalizedwith various
comorbidities. Fungal sepsis is predominantly caused by Candida spe-
cies and invasive candidiasis represents the fourthmost commonhealth
care–associated bloodstream infection [4]. In addition to primary fungalDepartment of Anesthesiology
127 Bonn, Germany.
.
lly to this work.
. This is an open access article undersepsis, secondary systemic fungal infections often develop in the course
of a bacterial infection due to sepsis-associated immune paralysis [5].
The host's innate immunity plays a critical role in the early onset of a
fungal infection [6]. Fungal cell-wall components such as zymosan,
phospholipomannan, bbetaN-glucan, and glucuronoxylomannan act
as pathogen associated molecular patterns (PAMPs) and activate differ-
ent pattern recognition receptors (PRRs), including toll-like receptors
(TLRs), C-type lectin receptors and the galectin family proteins [7]. Acti-
vation of PRRs expressed bymonocytes leads to the transcription of NF-
κB-dependent pro-inﬂammatory cytokines, which further orchestrate
the immune response of the host to fungal microorganisms [8].
Phagocytosis is a key mechanism in the innate immune response
and is decisive for both bacterial and fungal clearance. Enzymes such
as inducible nitric oxide synthase (iNOS) and themultiprotein complex
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase man-
age intracellular oxidative pathways, collectively referred to as thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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gen intermediates (ROI) that inevitably damage fungal pathogens by
protein modiﬁcations, nucleic-acid breaks and lipid peroxidations [9].
Microbial components activate the production of ROI that is enhanced
by opsonins and cytokines.
Delayed administration of antifungal agents is associated with in-
creased mortality [10]. However, the underlying mechanisms leading
to poor survival remain elusive. Antifungal drugs destroy microorgan-
isms either by inhibiting cell wall synthesis (anidulafungin,
itraconazole), inhibiting pore formation in the cell membrane or via ox-
idative damage (amphotericin B) [11–13].
Antimycotics also direct immunomodulatory effects, such as trigger-
ing the release of pro-inﬂammatory cytokines and chemokines [14,15].
However, these immunomodulatory effects have only been investigated
in the presence of fungal pathogens, and the presence of other microor-
ganisms during antifungal treatment has not been fully explored. Criti-
cally ill patients are vulnerable to a degradation of the intestinal barrier,
rendering them susceptible to bloodstream infectionwith enteric bacte-
ria and bacterial-induced immunosuppression. Thus, subsequent fungal
infections can often develop as a second hit in these immunocompro-
mised patients [16,17]. Among immunocompromised patients, addi-
tional direct modulation of immune status by antifungal agents
decisively impacts clinical outcome. As the effects of antifungal agents
on the innate immune response during inﬂammation are incompletely
understood, we investigated whether antimycotics, including polyenes,
azoles, and echinocandins, directly modulate the innate immune re-
sponse in a model of inﬂammation in the presence and absence of
lipopolysaccharide(LPS) in THP-1 monocytes.
Our study found that all tested antimycotics differentially modulate
gene and protein levels of TNF-balphaN, IL-1bbetaN, IL-6, IL-10, and IL-
1ra in LPS-activated human monocytes. The investigated antifungal
drugs also differentially regulate the phagocytic activity of monocytes.
2. Material and methods
2.1. Cell culture and reagents
Cell culture techniques followed a previously described protocol
[18]. Brieﬂy, human monocyte THP-1 cells (ATCC TIB-202) were
grown in suspension in RPMI 1640 (PAA, Coelbe, Germany) containing
10% fetal calf serum (FCS Biochrom, Berlin, Germany), 0.05 mM 2-
mercaptoethanol (Sigma-Aldrich, Taufkirchen, Germany), 100 μg/ml
penicillin, 100 mg/ml streptomycin (both Invitrogen, Frankfurt,
Germany) andwere maintained at 37 °C in a humidiﬁed incubator con-
taining 5% CO2. The cells were cultured in antibiotic- and FCS-free sus-
pension for 48 h before experimental use to avoid any confounding
stimulation that might result from antibiotics or endotoxins contained
in the cell culture medium. The viability of monocytes was determined
by the trypan blue staining method. Cells with a viability higher than
90% were used for the following experiments.
LPS (Escherichia coli serotype 055:B5) was purchased from Sigma-
Aldrich (Taufkirchen, Germany) and antifungal drugs were obtained
from the following manufacturers: liposomal amphotericin B (L-AMB)
from Gilead (Foster City, CA, USA); anidulafungin (ANI) from Pﬁzer
(New York City, NY, USA) and itraconazol (ITC) from Janssen-Cilag
(Neuss, Germany).
2.2. In vitro co-stimulation experiments
THP-1 cells were incubated at a concentration of 1 × 106 cells/ml in
6-well plates (Cellstar, greiner bio-one, Frickenhausen, Germany) in the
presence of LPS (10 μg/ml), L-AMB (7 μg/ml), ANI (7 μg/ml), ITC (2 μg/ml)
or a combination of LPSwith each antifungal agent. After 2 h, 6 h and24h,
cell culture supernatants were collected and mRNA was isolated from
monocytes and stored at−80 °C for further analysis.To assess cell viability of monocytes in the experiments described
above, the annexin-V and PI double staining method was used. THP-1
cells were incubated with antifungals in the presence or absence of
LPS for 24 h and then stained with the annexin V-FITC Apoptosis Detec-
tion Kit (Invitrogen) according to manufacturer's protocols. Stained
cells were immediately subjected to ﬂow cytometry analyses using a
FACS Canto III ﬂow cytometer (BD Biosciences) (Supplemental Fig. 1).
2.3. Isolation of RNA and Real-time PCR
Total RNA was isolated from THP-1 cells using the RNeasy mini kit
(Qiagen, Hilden, Germany) according to the manufacturer's instruc-
tions. cDNA was generated from total RNA with the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Darmstadt,
Germany) as recommended by the manufacturer. Cycling conditions
were 25 °C for 10 min, 37 °C for 120 min, and 85 °C for 5 s. Real-time
PCR was carried out on the 7900HT Fast Real-Time PCR system of Ap-
plied Biosystems using TaqMan Gene Expression Assays primer/probe
sets (Applied Biosystems) and the standard thermal-cycling conditions
for relative quantiﬁcation designed by the manufacturer. The following
TaqMan primer/probe sets were used: IL-6 (Hs00985639_m1), IL-10
(Hs00174086_m1), TNF-balpha (Hs99999043_m1) and IL-1bbetaN
(Hs00174097_m1).
Quantiﬁcation of the PCR signals for each sample involved compar-
ing cycle threshold values in duplicate for the gene of interest with
the cycle threshold values for the GAPDH housekeeping gene. The
mean relativemRNA expressionwas determinedwith the SDS software
V2.2 on the system using the 2−ΔΔCT method.
2.4. Measurement of cytokine levels by ELISA
TNF-balphaN, IL-1bbetaN, IL-6, IL-10, and IL-1ra levels in the cell
culture supernatant were quantiﬁed using commercially available
ELISA kits (BDOptiEIA, BD Biosciences, Heidelberg, Germany) according
to manufacturer instructions.
2.5. Phagocytosis assay
Phagocytosis by THP-1 cells was assayed using the pHrodo E. coli
BioParticles Conjugate assay (Invitrogen), as described by Wan et al.
and according to manufacturer instructions [19]. Brieﬂy: to prepare
BioParticles, 2 ml of PBS were used for reconstitution; THP-1 cells
(1 × 106 cells/ml) were incubated with antifungal agents as described
above in the presence or absence of LPS for 24 h, followed by an addi-
tional incubation with pHrodo E. coli BioParticles for 2 h. DNA staining
for viability measurements was done just prior to ﬂow cytometry anal-
ysiswithHoechst 33342 (Invitrogen) at a concentration of 2 μg/ml. Flow
cytometry was conducted using a Canto III Flow Cytometer System (BD
Biosciences, Heidelberg, Germany) and FlowJo Analysis Software
(Treestar, Ashland, OR, USA). Phagocytic activity was expressed as the
percentage of cells from the total number of viable monocytes that per-
formed phagocytosis.
2.6. Statistical analysis
Statistical analysis was performed using GraphPad Prism 5
(GraphPad Software, La Jolla, CA, USA). Mann–Whitney U test was
used to examine differences in phagocytic assay, gene expression and
protein levels. Values of p b 0.05 were considered signiﬁcant. All data
are expressed as mean ± SEM unless otherwise noted.
3. Results
To examine whether common classes of antifungal drugs modulate
the gene expression of pro- and anti-inﬂammatory cytokines that are
critical in the development of sepsis, monocytes were incubated with
130 S. Muenster et al. / Life Sciences 141 (2015) 128–136clinically relevant concentrations of polyenes (L-AMB), azoles (ITC), and
echinocandins (ANI) in the presence or absence of LPS, in order to
achieve pre-stimulated immune status due to bacterial components.
3.1. Antifungal agents modulate TNF-balphaN gene expression levels in the
presence and absence of LPS in human monocytes
As shown in Fig. 1A–C, the stimulation of monocytes with antifungal
agents in the presence and absence of LPS differentially modulated the
gene expression of the pro-inﬂammatory cytokine TNF-balphaN over
time. The immunostimulatory potency varied between the different
compounds.
Mono-stimulation with ITC signiﬁcantly upregulated TNF-balphaN
gene expression levels at all investigated time points with a maximum
at 24 h when compared to the respective unstimulated controls
(Fig. 1A–C, p b 0.05). The gene expression further increased up to a
3.7-fold after 24 h when monocytes were co-stimulated with LPS
(Fig. 1C, p b 0.05).
Mono-stimulation with ANI enhanced TNF-balphaN expression
levels signiﬁcantly up to 1.6-fold after 6 h and 2.7-fold after 24 h incuba-
tion when compared to unstimulated controls (Fig. 1B and C, p b 0.05).
Co-stimulation with LPS had no effect on TNF-balphaN gene expression
at 2 h and 6 h, although mRNA levels were higher at 24 h compared to
respective LPS controls (Fig. 1A–C, p b 0.05).
In contrast, L-AMB in combination with LPS down-regulated TNF-
balphaN gene expression compared to LPS-activated controls at all in-
vestigated time points (Fig. 1A–C, p b 0.05). L-AMB mono-stimulationFig. 1. Effect of antifungal compounds on TNF-balphaN gene expression levels in unstimulated
amphotericin B (L-AMB), anidulafungin (ANI) or itraconazole (ITC) in the presence or absence
levels of TNF-balphaN (A–C) after normalization to GAPDH. Each column represents the fold-cha
to unstimulated controls or co-incubation of LPS-treated cells with an antifungal compound. Da
unstimulated controls, p b 0.05, (+) mean antifungal drug co-stimulation in LPS-treated cellsdecreased TNF-balphaN gene expression levels at 6 h compared to
unstimulated monocytes (Fig. 1B, p b 0.05).
These ﬁndings suggest that, in the presence of LPS, L-AMB sup-
pressed the gene expression of the pro-inﬂammatory cytokine TNF-
balphaN whereas ITC enhanced the TNF-balphaN gene expression in
LPS-activated monocytes. ANI mono-stimulation triggered an increase
in TNF-balphaN gene expression whereas this effect was reduced in
the presence of LPS.
3.2. Antifungal compounds signiﬁcantly affect Interleukin-1bbetaN gene
expression levels in the presence of LPS in human monocytes
IL-1bbetaN is a pro-inﬂammatory cytokine and an important medi-
ator of the inﬂammatory response during sepsis. We investigated gene
expression levels of IL-1bbetaN during stimulation with antifungal
compounds in unstimulated and LPS-activated human monocytes.
ITC and LPS co-stimulation enhanced IL-1bbetaN gene expression
levels up to 9.4-fold after 2 h of incubation (Fig. 2A, p b 0.05). These ef-
fects persisted with a 9.6-fold change after 6 h (Fig. 2B, p b 0.05).
Co-incubation of ANI and LPS induced comparable pro-
inﬂammatory effects: there was as much as a 7.9 fold increase in IL-
1bbetaNmRNA levels after 2 h (Fig. 2A, p b 0.05) and 13-fold elevation
after 6 h when compared to LPS-activated controls (Fig. 2B, p b 0.05).
Further, L-AMB signiﬁcantly increased IL-1bbetaN gene expression
in LPS-activated monocytes at 2 h and 6 h. Moreover, IL-1bbetaN gene
expression levels were reduced after 24 h in the presence of L-AMB
and ANI when cells were treated with LPS, as shown in Fig. 2C.and LPS-activated THP-1 monocytes. Human monocytes were incubated with liposomal
of LPS for 2 h, 6 h and 24 h, respectively. qPCR was performed to measure gene expression
nge ofmRNA expression levels comparing eithermono-incubationwith anantifungal drug
ta are expressed asmean± SEM, (*) mean antifungal drugmono-incubation versusmean
versus LPS-controls, p b 0.05.
Fig. 2. Effect of antifungal compounds on IL-1bbetaN cytokine gene expression levels in unstimulated and LPS-activated THP-1monocytes. Humanmonocytes were incubated with lipo-
somal amphotericin B (L-AMB), anidulafungin (ANI) or itraconazole (ITC) in the presence or absence of LPS for 2 h, 6 h and 24 h, respectively. qPCR was performed to measure gene ex-
pression levels of IL-1bbetaN (A–C), after normalization to GAPDH. Each column represents the fold-change of mRNA expression levels comparing either mono-incubation with an
antifungal drug to unstimulated controls or co-incubation of LPS-treated cells with an antifungal compound. Data are expressed asmean± SEM, (*) mean antifungal drugmono-incuba-
tion versus mean unstimulated controls, p b 0.05, (+) mean antifungal drug co-stimulation in LPS-treated cells versus LPS-controls, p b 0.05.
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moderate effects on IL-1bbetaN gene expression levels (Fig. 2A, p b
0.05).
These results demonstrate that ANI and ITC have strong pro-
inﬂammatory properties in the presence of LPS, whereas L-AMB had
the lowest level of enhanced IL-1bbetaN gene expression. Consistent
with results described above, these ﬁnding suggest a suppressed pro-
inﬂammatory response of L-AMB in the presence of LPS.3.3. Antifungal agents in the presence and absence of LPS in THP-1 mono-
cytes differentially regulate Interleukin-6 gene expression levels
IL-6 is an important pro-inﬂammatory mediator during the inﬂam-
matory response and activates the production of anti-inﬂammatory
proteins such as IL-10 and IL-1ra. Therefore, gene expression levels of
IL-6 were investigated in unstimulated and LPS-activated monocytes
when stimulated with antimycotics.
At all time points, L-AMB signiﬁcantly reduced the mRNA-levels of
IL-6 in LPS-activated monocytes when compared to the respective con-
trols (Fig. 3A–C, p b 0.05). In addition, the same effect of L-AMB on IL-6
gene expression was observed in unstimulated monocytes (Fig. 3A–C,
p b 0.05).
Mono-incubation of THP-1 cells with ANI reduced IL-6 gene expres-
sion levels after 2 h and 6 h (Fig. 3A and B, p b 0.05) while ANI in LPS-
activated monocytes lowered IL-6 mRNA levels only at 2 h (Fig. 3B,
p b 0.05).When monocytes were incubated with ITC alone, IL-6 gene expres-
sion levels increased approximately 2-fold at 6 h (Fig. 3B, p b 0.05),
whereas co-stimulation with LPS increased IL-6 mRNA levels signiﬁ-
cantly after only 2 h (Fig. 3A, p b 0.05) with a peak at 6 h (4.2-fold
change, Fig. 3B, p b 0.05). At 24 h, ITC in combination with LPS reduced
IL-6 gene expression by 50% compared to LPS stimulated controls
(Fig. 3C, p b 0.05).
These results again demonstrate that L-AMB suppressed the gene
expression of the pro-inﬂammatory response during inﬂammation
whereas ITC enhanced this response.3.4. Antifungal agents in the presence and absence of LPS in THP-1 mono-
cytes differentially regulate Interleukin-10 gene expression levels
The cytokine IL-10 is crucial for the anti-inﬂammatory response dur-
ing inﬂammation. To examine if antifungal compounds potentially en-
hance IL-10 gene expression, mRNA levels of IL-10 were measured
after stimulation with different antimycotics after 2 h, 6 h and 24 h in
both unstimulated and LPS-activated monocytes.
Mono-stimulationwith L-AMB increased IL-10 gene expression after
2 h and 24 h when compared to unstimulated controls (Fig. 4A and C,
p b 0.05). In contrast, L-AMB reduced IL-10 gene expression after 6 h
when compared to LPS controls, whereas L-AMB and LPS increased IL-
10 mRNA levels after 24 h (Fig. 4B and C, p b 0.05).
Mono-stimulation with ANI increased IL-10 gene expression after
6 h and 24 h compared to unstimulated controls (Fig. 4B and C, p b
Fig. 3. Effect of antifungal compounds on IL-6 cytokine gene expression levels in unstimulated and LPS-activated THP-1 monocytes. Human monocytes were incubated with liposomal
amphotericin B (L-AMB), anidulafungin (ANI) or itraconazole (ITC) in the presence or absence of LPS for 2 h, 6 h and 24 h, respectively. qPCR was performed to measure gene expression
levels of IL-6 (A–C), after normalization to GAPDH. Each column represents the fold-change of mRNA expression levels comparing either mono-incubation with an antifungal drug to
unstimulated controls or co-incubation of LPS-treated cells with an antifungal compound. Data are expressed as mean ± SEM, (*) mean antifungal drug mono-incubation versus mean
unstimulated controls, p b 0.05, (+) mean antifungal drug co-stimulation in LPS-treated cells versus LPS-controls, p b 0.05.
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after 6 and 24 h when compared to LPS-activated controls.
Mono-stimulation with ITC only increased IL-10 gene expression
after 24 h when compared with unstimulated controls (Fig. 4C, p b
0.05). Co-stimulation with ITC and LPS decreased IL-10 mRNA levels
after 6 h and 24 h when compared to LPS-activated controls (Fig. 4B
and C, p b 0.05).
These ﬁndings suggest that L-AMB, ANI, and ITC have anti-
inﬂammatory properties in unstimulated monocytes whereas the anti-
inﬂammatory effect of all tested compounds was absent in LPS-
activated monocytes.
3.5. Antifungal agents regulate TNF-balphaN, IL-1bbetaN, IL-6, IL-10 and
IL-1ra protein levels in the presence of LPS in THP-1-cells
To determine whether protein levels of TNF-balphaN, IL-1bbetaN,
IL-6, IL-10, and IL-1ra correlate with respective gene expression levels,
cell culture supernatant was collected after 6 h and 24 h of stimulation
with antifungal agents to measure cytokine protein levels in both
unstimulated and LPS-activated monocytes.
After 6 h, TNF-balphaN protein levels were decreased in ITC mono-
stimulated THP-1 cells, when compared with unstimulated controls
(Supplemental Fig. 2A, p b 0.05). In contrast, neither of the tested
antimycotic drugs in co-stimulation with LPS altered TNF-balphaN
levels when compared with LPS-activated monocytes. After 24 h, TNF-
balphaN protein levels increased more than 12-fold after co-
stimulationwith ITC and LPS when compared with LPS-treated controls(Fig. 5A, p b 0.05). In addition, ANI and LPS co-stimulation doubled TNF-
balphaN cytokine levels after 24 h (Fig. 5A, p b 0.05).
Co-stimulation of ITC and LPS increased IL-1bbetaN levels when
compared to LPS controls at 6 h (Supplemental Fig. 2B, p b 0.05).
After 24 h, IL-1bbetaN protein levels were more than doubled
when monocytes were co-incubated with LPS and ITC (Fig. 5B,
p b 0.05). In contrast, incubation of monocytes with L-AMB in the
presence of LPS reduced IL-1bbetaN cytokine levels by approxi-
mately 26% (Fig. 5B, p b 0.05).
After 6 h, IL-6 levels were decreasedwhen LPS-activated THP-1 cells
were stimulated with ITC (Supplemental Fig. 2C, p b 0.05). Co-
stimulation of L-AMB and LPS decreased IL-6 levels protein levels after
24 h when compared to LPS controls (Fig. 5C, p b 0.05).
After 6 h, ITCmono-stimulation decreased IL-10 protein levels when
compared to unstimulated THP-1 cells (Supplemental Fig. 2D, p b 0.05).
In contrast, all tested antifungal compounds increased IL-10 levels in
LPS-stimulated monocytes (Supplemental Fig. 2D, p b 0.05). After
24 h, IL-10 protein levels were increased in both unstimulated and
LPS-activated monocytes when stimulated with ANI (Fig. 5D, p b
0.05). In addition, co-stimulation with L-AMB and LPS increased IL-10
levels when compared to LPS-stimulated controls (Fig. 5D, p b 0.05).
After 24 h, IL-1ra levels were decreased when LPS-activated mono-
cytes were stimulated with L-AMB (Fig. 5E, p b 0.05) whereas all other
antifungal compounds showed no effect on IL-1ra levels in either
unstimulated or LPS-activated THP-1 cells.
The IL-1ra/IL-1bbetaN ratio of total cytokines produced by THP-1
was calculated to determine whether or not an imbalance between
Fig. 4. Effect of antifungal compounds on IL-10 cytokine gene expression levels in unstimulated and LPS-activated THP-1 monocytes. Human monocytes were incubated with liposomal
amphotericin B (L-AMB), anidulafungin (ANI) or itraconazole (ITC) in the presence or absence of LPS for 2 h, 6 h and 24 h, respectively. qPCR was performed to measure gene expression
levels of IL-10 (A–C), after normalization to GAPDH. Each column represents the fold-change of mRNA expression levels comparing either mono-incubation with an antifungal drug to
unstimulated controls or co-incubation of LPS-treated cells with an antifungal compound. Data are expressed as mean ± SEM, (*) mean antifungal drug mono-incubation versus mean
unstimulated controls, p b 0.05, (+) mean antifungal drug co-stimulation in LPS-treated cells versus LPS-controls, p b 0.05.
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after stimulation with respective antimycotics in unstimulated or LPS-
activated monocytes [20]. The IL-1ra/IL-1bbetaN ratio increased after
24 h, when unstimulated monocytes were stimulated with ANI
(Fig. 5F, p b 0.05). ITC stimulation decreased the IL-1ra/IL-1bbetaN
ratio after 24 h in LPS-activated THP-1 cells (Fig. 5F, p b 0.05).
These results suggest that L-AMB, in the presence of LPS, act as an
immunosuppressive compound whereas ITC showed remarkable pro-
inﬂammatory properties. In contrast, the effects of ANI in LPS-
activated monocytes were more variable.3.6. Effect of antifungal antibiotics on phagocytic activity
Phagocytosis is a critical mechanism of the innate immune defense
to eliminate invading microorganisms [21]. Therefore, we investigated
whether phagocytic activity in both LPS-activated and unstimulated
human monocytes was modulated in the presence of antifungal
compounds.
Incubation of unstimulated cells with ANI showed a signiﬁcant in-
crease by 77.2% of the phagocytic activity when compared to untreated
controls (Fig. 6A, p b 0.05), whereas L-AMB or ITC mono-stimulation
showed no signiﬁcant effects. In LPS-activated monocytes, L-AMB and
ITC considerably decreased phagocytic activity by 34.7% and 79.5%, re-
spectively (Fig. 6B, p b 0.05). In contrast, the phagocytic activity did
not change when LPS-activated THP-1 cells were co-incubated with
ANI.These ﬁndings demonstrate that ANI mono-stimulation increased
the phagocytic activity in unstimulated THP-1 cells, whereas L-AMB
and ITC decreased phagocytosis in LPS-activated monocytes.4. Discussion
We used a well-established LPS-induced in vitro sepsis model to ini-
tially investigate whether antifungal compounds possess direct immu-
nomodulatory properties in response to bacterial pathogens, LPS is
commonly used in in vitro and in vivomodels of sepsis and the adminis-
tration to human subjects mimics many of the features of sepsis [22]. In
critically ill patients, increased concentrations of serum LPS have been
associatedwith the development of sepsis, disease severity, andmortal-
ity [23]. Thus, the use of LPS is of value to test the immunomodulatory
potential of antifungal compounds on the immune response in septic
conditions. Albeit the stimulation of monocytes by LPS is a basic ap-
proach, this model is widely recognized to test the effects of immuno-
modulatory agents on the immune response in septic conditions [24,
25].
This study demonstrates that polyenes (L-AMB), azoles (ITC), and
echinocandins (ANI) differentially modulate both the gene expression
and protein levels of inﬂammatory cytokines in humanmonocytes. Spe-
ciﬁcally, these immunomodulatory effects are increased in the presence
of LPS. In addition, all tested antifungal compounds differentially regu-
lated the phagocytic activity of monocytes either in the presence or ab-
sence of LPS-stimulation.
Fig. 5. Effect of antifungal drugs on cytokine protein levels in unstimulated and LPS-activated THP-1 monocytes. Human monocytes were incubated with liposomal amphotericin B (L-
AMB), anidulafungin (ANI) or itraconazole (ITC) in the presence or absence of LPS for 24 h. Cell culture supernatants were analyzed for protein levels of TNF-balphaN (A), IL-1bbetaN
(B), IL-6 (C), IL-10 (D), and IL-1ra (E) respectively. The IL-1ra/IL-1bbetaN ratio of total cytokines produced by THP-1 was calculated to determine whether or not an imbalance between
anti-inﬂammatory IL-1ra and pro-inﬂammatory IL-1bbetaN occurred after stimulation with respective antimycotics in unstimulated or LPS-activated monocytes. Data are expressed as
mean ± SEM, (#) represents unstimulated controls versus LPS-stimulated control cells, p b 0.05, (+) represents LPS-treated controls versus co-stimulation of an antifungal compound
in endotoxin-activated monocytes, p b 0.05.
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stimulation reduced TNF-balphaN and IL-1bbetaN gene expression
levels [20,26]. Furthermore, IL-6 protein levels were slightly elevated
as was also reported by Olson and colleagues [27]. Our studies suggest
that the immunosuppressive properties of L-AMB are enhanced when
monocytes are co-stimulated with LPS - an observation that might beof relevance for the treatment of septic patients with bacteremia and
secondary fungal infections. We further demonstrated that L-AMB
inhibited the TNF-balphaN and IL-6 gene expression in LPS-activated
monocytes compared to LPS-controls. These results are consistent
with the cytokine protein levels thatweremeasured after 24 h. Interest-
ingly, co-stimulationwith L-AMB and LPS initially enhanced IL-1bbetaN
Fig. 6. Effects of antifungal compounds on phagocytosis of heat-inactivated E. coli in unstimulated and LPS-activated THP-1 monocytes. (A) Monocytes were mono-incubated with lipo-
somal amphotericin B (L-AMB), anidulafungin (ANI) or itraconazole (ITC) respectively or (B) co-incubated with L-AMB, ANI or ITC in the presence of LPS for 24 h. THP-1 cells were incu-
bated thereafter for 2 hwith heat-killed rhodamine-conjugated E. coli and phagocytosiswas determined by ﬂow cytometry. Data showpercentage ofmonocytes positive for phagocytosis
determined and are expressed asmean± SEM, (*) unstimulated controls versusmono-incubation with an antifungal compound, p b 0.05; (+) LPS-treated controls versus co-incubation
of antifungal drugs in LPS-activated cells, p b 0.05.
135S. Muenster et al. / Life Sciences 141 (2015) 128–136gene expression levels, whereas IL-1bbetaNmRNA levels were signiﬁ-
cantly down-regulated after 24 h. Moreover, IL-1bbetaN protein levels
after 24 h were signiﬁcantly lower when co-stimulated with L-AMB
and LPS, by comparison to respective LPS-controls. These ﬁndings sug-
gest that L-AMB effects on increased IL-1bbetaN mRNA levels are
short-term and do not lead to a subsequent increase of protein levels.
This demonstrates that L-AMBdecreases IL-1bbetaN cytokine levels, in-
dicating a predominant immunosuppressive effect of L-AMB on LPS-
activated monocytes. Bellocchio and colleagues showed that L-AMB
mono-stimulation diverts TLR signaling from TLR2 (activated by D-
AMB and responsible for pro-inﬂammatory activities) to TLR4 and
thereby activates amore anti-inﬂammatory pattern of cytokine produc-
tion (e.g., enhanced IL-10 cytokine levels) [28,29]. This hypothesis may
further explain the immunosuppressive properties of L-AMB in LPS-
activated monocytes possibly by either a receptor-competition of L-
AMB and of the TLR4 ligand LPS [30] or synergistic ligand-binding ef-
fects of both L-AMB and LPS. Indeed, we found slightly elevated IL-10
protein levels and a reduced IL-1ra/IL-1bbetaN ratio 24 h after L-AMB
stimulation in LPS-activated monocytes. A possible explanation for the
small increase in IL-10 levels in THP-1 cells in response to LPS has
been suggested by Schildberger and colleagues. The authors found
that THP-1 cells failed to produce IL-10 during stimulation with LPS
when compared to human unstimulated monocytes and PBMCs [31].
Therefore, it is likely that treatmentwith antifungal compoundsmay re-
veal another outcome on IL-10 levels in humans - a hypothesis that
needs to be tested in further studies in humans with secondary fungal
infections.
Other studies demonstrated that the co-incubation of ANI with Can-
dida albicans bioﬁlms increases TNF-balphaN protein production of
THP-1 cells [32]. Here, we were able to show elevated TNF-balphaN
mRNA levels in ANI stimulated monocytes whereas TNF-balphaN pro-
tein levels only showed a trend. We also demonstrated that LPS and
ANI co-stimulation led to signiﬁcant elevated TNF-balphaN mRNA and
protein levels. In addition, we found that IL-6 mRNA levels were signif-
icantly lower during the earlier time points of mono-incubation with
ANI, whereas this effect was only observed after 2 h in LPS co-
stimulated cells. To our knowledge, there are no preexisting data
about the effects of ANI on IL-1bbetaN gene expression in human
monocytes. Our study further showed that co-stimulation ofmonocytes
with ANI and LPS resulted in strong elevation of IL-1bbetaN mRNA
levels after 2 h and 6 h of incubation time whereas ANI mono-
stimulation showed only moderate effects after 24 h on the IL-
1bbetaN mRNA levels. Consistent with the work of Baltch andcolleagues, ANI and LPS co-stimulation had no signiﬁcant effect on IL-
1bbetaN and IL-6 protein levels after 24 h [33]. The authors assume
that the combination of infection (LPS) and echinocandins presumably
leads to inhibitory effects on the endoplasmatic reticulum to secret cy-
tokines and chemokines [34,35], or the protein response inhibits with
a negative feedbackmechanism further intracellular protein translation
[36,37]. Theseﬁndingsmay explain thediscrepancy between altered cy-
tokinemRNA levels and absence of any effect on protein levels. Howev-
er, TNF-balphaN gene expression and protein levels obviously exhibited
a different intracellular pattern.
Kato and colleagues reported elevated TNF-balphaN and IL-1bbetaN
protein levels after 24 h in mouse macrophage-like cells during ITC and
LPS co-stimulation in vitro [38]. Our data further support these results
by demonstrating signiﬁcantly higher mRNA and correlating protein
levels for TNF-balphaN and IL-1bbetaN during ITC and LPS co-
stimulation. In addition, we demonstrated that ITC strongly enhanced
IL-6 mRNA as well as protein levels in LPS-activated monocytes. There
is evidence that the antifungal azole voriconazole increases TLR2 ex-
pression and enhances the RelA (p65) NF-κB dimer levels in nuclear ex-
tracts of THP-1 monocytes when incubated with voriconazole,
Aspergillus fumigatus hyphae or both [39]. In our study, azole ITC
might facilitate the translocation of NF-κB into the nucleus to enhance
pro-inﬂammatory cytokines gene expression, which has been sug-
gested for voriconazole by Simitsopoulou and colleagues [39].
There is evidence that amphotericin B increases the killing activity of
monocytes [40]. However, we only identiﬁed a trend towards enhanced
phagocytic activity in our study. Our data showed that L-AMB inhibits
the phagocytic activity in LPS-pretreated monocytes. This result sug-
gests that L-AMBmay reduce the phagocytosis of pathogens in bacterial
sepsis. Frank and colleagues reported that ANImono-stimulation signif-
icantly improved intracellular killing rates of human phagocytes [41].
We found enhanced phagocytic activity when native monocytes were
incubated with ANI, which was absent during LPS co-stimulation. This
result emphasizes that immunomodulatory effects enhanced by the an-
tifungal compound ANI are abolishedwhen additional septic conditions
(caused by bacterial fragments) are present. Interestingly, ITC mono-
stimulation showed no differences compared to unstimulated controls.
This ﬁnding contradicts previous published results using itraconazole to
stimulate monocytes [42]. However, Nino et al. observed the maximum
effect after 16 h of ITC mono-incubation whereas our samples were in-
cubated for 24 h beforemonocytes were exposed to E. coli, whichmight
explain of the different ﬁndings in the phagocytic activity of native
monocytes.
136 S. Muenster et al. / Life Sciences 141 (2015) 128–1365. Conclusion
In line with previous studies demonstrating modulation of the im-
mune response as a promising strategy in the treatment of severely ill
patients, especially in those who are immunocompromised [6,43], we
identiﬁed L-AMB as immunosuppressive, whereas ITC demonstrated
pro-inﬂammatory properties. Current studies suggest that common
classes of antifungal compounds used in septic patients alter the im-
mune response in sepsis-like conditions by modulating both the cyto-
kine expression and the phagocytic activity.
In our study, both L-AMB and ITC reduced phagocytic activity in LPS-
stimulated monocytes. Thus, future treatment strategies should consider
the immune status of the host and apply antifungal agents accordingly in
bacterial septic patients with secondary fungal infections. Based on cur-
rent ﬁndings future in vivo studies should evaluate immunomodulation
by L-AMB and ITC as a therapeutic strategy in sepsis.
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